JP2012502663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502663A5 JP2012502663A5 JP2011528039A JP2011528039A JP2012502663A5 JP 2012502663 A5 JP2012502663 A5 JP 2012502663A5 JP 2011528039 A JP2011528039 A JP 2011528039A JP 2011528039 A JP2011528039 A JP 2011528039A JP 2012502663 A5 JP2012502663 A5 JP 2012502663A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- immunogenic
- antibody
- dna molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 230000002163 immunogen Effects 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 16
- 108020004414 DNA Proteins 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 102000053602 DNA Human genes 0.000 claims 12
- 241000606161 Chlamydia Species 0.000 claims 9
- 230000005875 antibody response Effects 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 230000003302 anti-idiotype Effects 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 238000003018 immunoassay Methods 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000000412 dendrimer Substances 0.000 claims 3
- 229920000736 dendritic polymer Polymers 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 208000007190 Chlamydia Infections Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 108010088535 Pep-1 peptide Proteins 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000007918 pathogenicity Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 claims 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 claims 1
- 241000724791 Filamentous phage Species 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 101800001707 Spacer peptide Proteins 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 108010037248 lantibiotic Pep5 Proteins 0.000 claims 1
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9876908P | 2008-09-21 | 2008-09-21 | |
| US61/098,769 | 2008-09-21 | ||
| PCT/US2009/057700 WO2010033923A2 (en) | 2008-09-21 | 2009-09-21 | Genus-wide chlamydial peptide vaccine antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502663A JP2012502663A (ja) | 2012-02-02 |
| JP2012502663A5 true JP2012502663A5 (https=) | 2012-11-08 |
| JP5798034B2 JP5798034B2 (ja) | 2015-10-21 |
Family
ID=42040185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011528039A Expired - Fee Related JP5798034B2 (ja) | 2008-09-21 | 2009-09-21 | クラミジア属にわたる（Ｇｅｎｕｓ−ＷｉｄｅＣｈｌａｍｙｄｉａｌ）ペプチドワクチン抗原 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8637040B2 (https=) |
| EP (1) | EP2337789A4 (https=) |
| JP (1) | JP5798034B2 (https=) |
| AU (1) | AU2009292970B2 (https=) |
| CA (1) | CA2774336A1 (https=) |
| WO (1) | WO2010033923A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9408906B2 (en) * | 2010-06-04 | 2016-08-09 | Flow Pharma, Inc. | Peptide particle formulation |
| US10293044B2 (en) | 2014-04-18 | 2019-05-21 | Auburn University | Particulate formulations for improving feed conversion rate in a subject |
| US20150297706A1 (en) * | 2014-04-18 | 2015-10-22 | Auburn University | Particulate Vaccine Formulations for Inducing Innate and Adaptive Immunity |
| JP2023529557A (ja) | 2020-05-04 | 2023-07-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｎｐｐ１抗体の阻害 |
| EP4661878A2 (en) * | 2023-02-07 | 2025-12-17 | Merck Sharp & Dohme LLC | Adjuvant formulations including low viscosity chitosan or chitosan derivatives |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
| US5840297A (en) * | 1993-03-19 | 1998-11-24 | Johns Hopkins University | Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process |
| US5656271A (en) | 1993-03-19 | 1997-08-12 | The Johns Hopkins University | Oral vaccine comprising anti-idiotypic antibody to chlamydia glycolipid exoantigen and process |
| WO1995024922A1 (en) | 1994-03-16 | 1995-09-21 | Alex Bruce Macdonald | Chlamydia vaccines and process |
| US5716713A (en) * | 1994-12-16 | 1998-02-10 | Ceramic Packaging, Inc. | Stacked planar transformer |
| CA2405052A1 (en) | 2000-04-06 | 2001-10-18 | University Of Massachusetts | Chlamydial glycolipid vaccines |
| WO2003037172A2 (en) | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| EP1743172A2 (en) | 2004-04-16 | 2007-01-17 | University of Massachusetts | Detection and quantification of intracellular pathogens |
| US9051379B2 (en) * | 2005-07-07 | 2015-06-09 | Fulcrum Sp Ltd. | Sp1 polypeptides, modified Sp1 polypeptides and uses thereof |
| US20070065387A1 (en) * | 2005-09-16 | 2007-03-22 | Beck William A | Method for enhancing the effect of particulate benefit agents |
| US7928076B2 (en) * | 2005-12-15 | 2011-04-19 | E. I. Du Pont De Nemours And Company | Polypropylene binding peptides and methods of use |
-
2009
- 2009-09-21 US US13/120,071 patent/US8637040B2/en not_active Expired - Fee Related
- 2009-09-21 AU AU2009292970A patent/AU2009292970B2/en not_active Ceased
- 2009-09-21 JP JP2011528039A patent/JP5798034B2/ja not_active Expired - Fee Related
- 2009-09-21 WO PCT/US2009/057700 patent/WO2010033923A2/en not_active Ceased
- 2009-09-21 EP EP09815339A patent/EP2337789A4/en not_active Withdrawn
- 2009-09-21 CA CA2774336A patent/CA2774336A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| JP2023504914A5 (https=) | ||
| JP2013181034A5 (https=) | ||
| JP2012518425A5 (https=) | ||
| JP2013529078A5 (https=) | ||
| JP2020505034A5 (https=) | ||
| JP2018509907A5 (https=) | ||
| JP2008542278A5 (https=) | ||
| CA2477675A1 (en) | Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein | |
| Hong et al. | Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies | |
| ES2533493T3 (es) | Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato | |
| JP2021524270A5 (https=) | ||
| FR2955773A1 (fr) | Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination | |
| JP2026004299A5 (https=) | ||
| CA2363641A1 (en) | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses | |
| JP2021512159A5 (https=) | ||
| JP2012502663A5 (https=) | ||
| US20100028353A1 (en) | Anti-amyloid immunogenic compositions, methods and uses | |
| JP2023511963A5 (https=) | ||
| JP2022542670A5 (https=) | ||
| JP2017513854A (ja) | Ｗｉｓｐ１に結合する抗原結合タンパク質 | |
| JP2018510865A (ja) | Ｐｓｍａに結合する抗体医薬 | |
| JP2023544211A5 (https=) | ||
| KR20170052655A (ko) | 혈관내피 리파제의 효소 활성을 저해하는 인간화 모노클로널 항체 | |
| KR102427429B1 (ko) | 자기조립형 합성 단백질 |